In a revealing preclinical examine, the weight-loss drug tirzepatide—already recognized for combating weight problems and diabetes—unexpectedly slowed the expansion of breast most cancers tumors in overweight mice.
Researchers discovered that because the mice shed fats, their tumors shrank too, suggesting a direct hyperlink between weight reduction and lowered most cancers development.
Promising Weight problems Drug Curbs Breast Most cancers in Mice
A current examine offered at ENDO 2025, the annual assembly of the Endocrine Society in San Francisco, Calif., discovered that tirzepatide, a medicine authorized for kind 2 diabetes underneath the model title Mounjaro and for weight reduction as Zepbound, slowed the expansion of breast most cancers linked to weight problems in a mouse mannequin.
“Weight problems is a major threat issue for breast most cancers, and whereas it is extremely preliminary information, our research in mice counsel that these new anti-obesity medicine could also be a approach to scale back obesity-associated breast most cancers threat or enhance outcomes,” stated examine writer Amanda Kucinskas, B.S., a Ph.D. candidate within the labs of Drs. Erin Giles and Kanakadurga Singer on the College of Michigan in Ann Arbor, Mich.
Challenges of Conventional Weight Loss for Most cancers Prevention
Scientists have lengthy recognized that weight problems can result in worse outcomes for folks with breast most cancers, whereas weight reduction has been related to higher prognoses. Nevertheless, reaching and sustaining weight reduction by means of standard strategies stays tough for a lot of people.
To discover options, Kucinskas and her crew turned to tirzepatide. This medicine belongs to a brand new class of medicine that activate each GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, that are concerned in regulating blood sugar and urge for food. The researchers aimed to find out whether or not this drug may additionally sluggish the development of breast most cancers tied to weight problems.
Contained in the Mouse Examine Design
This mouse examine included 16 mice. The 9-week-old C57BL/6 mice have been fed a 40% high-fat eating regimen and housed in a heat surroundings to induce weight problems. At 32 weeks of age, the mice with weight problems have been randomly assigned injections of tirzepatide or a placebo each different day for 16 weeks. Tumor volumes have been measured twice weekly.
The researchers discovered that the anti-obesity drug lowered physique weight and physique fats by roughly 20% in mice, just like the quantity of weight reduction achieved by ladies on this drug. They discovered this was primarily on account of a lack of adipose mass, with a discount in adipose depot weights in comparison with controls.
Correlating Physique Weight With Tumor Progress
The anti-obesity drug additionally lowered tumor quantity in comparison with the controls. On the finish of the examine, the researchers discovered that tumor quantity was considerably correlated with physique weight, complete adipose mass and the quantity of fats saved within the liver.
“Whereas these are very preliminary outcomes, they counsel that this new anti-obesity drug may additionally have a helpful affect on breast most cancers outcomes,” Kucinskas stated.
Ongoing research are underway in collaboration with Dr. Steve Hursting’s lab on the College of North Carolina at Chapel Hill to separate the burden loss from the tumor-specific results of tirzepatide.
Assembly: ENDO 2025
By no means miss a breakthrough: Join the SciTechDaily newsletter.
